Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline in the Treatment of Visceral Sensation
NCT06854406Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of varenicline in irritable bowel syndrome (IBS), sponsored by Mayo Clinic. Primary endpoints: Rectal compliance at 8 days, Rectal sensation thresholds during ascending method of limits at 8 days and 1 more. Started Jun 2025; status: completed.
02
Drugs
varenicline
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06854406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854406.